

Gavi Outlook

- Recent accomplishments
- Updates
- Looking forward

DCVMN Annual General Meeting
October 2015




VACCINE INTRODUCTION GOALS MET IN 2014




Country introductions

(Number of countries)


Pentavalent vaccine



Pneumococcal vaccine




Rotavirus vaccine



* As of 16 July 2015.



Source: Gavi, 2015.

VACCINE INTRODUCTIONS AND CAMPAIGNS IN 2014



* Refers to annual birth cohort (for vaccine introductions)
or target population (for vaccine campaigns)

DCVMN IMPORTANT CONTRIBUTIONS



MORE SECURE VACCINE SUPPLY

2014: 16 manufacturers* from 11 countries of production




* Includes 14 Gavi suppliers and 2 manufacturers of prequalified Gavi vaccines.

** One US manufacturer also produces in the Netherlands.

Note: Country of production represents country of national regulatory agency responsible for vaccine lot release.


UPDATE: Country groupings and eligibility in 2016



UPDATE: Revisions to Gavi's co-financing policy


The Gavi Board adopted in June 2015 a revised *Co-financing* policy which brings two important changes:

➤ **Linking co-financing to prices for all countries in transition phases**



➤ **Development of payment plans to help countries get out of default**

SUCCESSFUL REPLENISHMENT: THE ASK FOR 2016–2020




**US\$ 7.5
billion**


additional funding
needed for immunisation
programmes through to 2020

STRATEGIC GOALS 2016–2020

Four strategic goals guide Gavi's mission




Introductions to peak in 2015 with IPV



CLOSING THE IMMUNISATION GAP

Vaccine coverage in Gavi-supported countries by 2020



Coverage refers to the final dose of each vaccine, unless otherwise stated.

^a Target population and coverage estimates are based on 32 yellow fever-endemic Gavi-supported countries in Africa.

^b Target population for HPV3 is 9-13 year old girls.

Sources: WHO/UNICEF coverage estimates and country official reported figures (MCV2 and rubella), as of July 2013. 2015 and 2020 coverage: Gavi strategic demand forecast version 9.

STRATEGIC GOALS 2016–2020

Four strategic goals guide Gavi's mission



**Vaccine
goal**

Accelerate
equitable uptake
and coverage of
vaccines



**Health
systems
goal**

Increase
effectiveness and
efficiency of
immunisation
delivery as an
integrated part of
strengthened health
systems



**Financing
goal**

Improve
sustainability of
national
immunisation
programmes



**Market
shaping
goal**

Shape markets for
vaccines and other
immunisation
products


Cold Chain Equipment Platform



Strengthen coverage and equity of immunisation

Equip 90,000 facilities with upgraded CCE and extend CCE to 45,000 unequipped facilities impacted by Platform, '000


Facilities impacted by Platform, '000



Promote the right technology for each facility

Help countries to choose the right technology & reduce closed vial wastage

Total cost of ownership USD



Incentivise reliable equipment performance

Improve technology design to mitigate common failures



STRATEGIC GOALS 2016–2020

Four strategic goals guide Gavi's mission



**Vaccine
goal**

Accelerate
equitable uptake
and coverage of
vaccines



**Health
systems
goal**

Increase
effectiveness and
efficiency of
immunisation
delivery as an
integrated part of
strengthened health
systems



**Financing
goal**


Improve
sustainability of
national
immunisation
programmes



**Market
shaping
goal**

Shape markets for
vaccines and other
immunisation
products

2016–2020: THE PROJECTED PEAK OF INVESTMENTS



STRATEGIC GOALS 2016–2020

Four strategic goals guide Gavi's mission



**Vaccine
goal**

Accelerate
equitable uptake
and coverage of
vaccines



**Health
systems
goal**

Increase
effectiveness and
efficiency of
immunisation
delivery as an
integrated part of
strengthened health
systems



**Financing
goal**


Improve
sustainability of
national
immunisation
programmes



**Market
shaping
goal**

Shape markets for
vaccines and other
immunisation
products

2011-2015 Supply & Procurement Strategy review and development of a revised strategy



- Review of objectives, scope
- Review of lessons learnt from strategy implementation and progress to date
- Consultations with stakeholders and partners
- Development of 2016-2020 Supply and Procurement Strategy

Considerations for a revised supply and procurement strategy

Current strategy provides strong foundation for the future

- 2011-2014 progress indicators
- Roadmaps, strategic demand forecasting and other core components to be maintained

Several factors will drive revisions in the strategy

- New directions in Gavi 4.0
 - Board-approved SG4 objectives and indicators:
 - Include other immunisation products, and
 - Innovation and healthy markets indicators
 - Coverage and equity
- Market shifts, e.g. 50% increase in # manufacturers
- Lessons learnt, e.g. needing a more explicit way of measuring trade-offs between objectives
- New opportunities to refine and strengthen tools and processes, e.g. expanding market-shaping partners

WHAT WE WILL ACHIEVE TOGETHER

2016–2020



additional children immunised

=



of total number of children
immunised in the world

#vaccineswork

THANK YOU

